PEAR THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
-.--% | -.--% |
| 03-22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
| 03-04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
| Sales 2021 | 4.21M 335M | Sales 2022 | 12.69M 1.01B | Capitalization | 165M 13.12B |
|---|---|---|---|---|---|
| Net income 2021 | -65M -5.18B | Net income 2022 | -75M -5.98B | EV / Sales 2021 | 168 x |
| Net cash position 2021 | 148M 11.76B | Net cash position 2022 | 21.66M 1.73B | EV / Sales 2022 | 11.3 x |
| P/E ratio 2021 |
-10.8
x | P/E ratio 2022 |
-2.17
x | Employees | 200 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 87.9% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -99.00% |
Current year
0.00
0.00
1 year
0.000.02
3 years
0.0014.60
5 years
0.0014.60
10 years
0.0014.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | - | |
Maria Sullivan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yuri Maricich
CTO | Chief Tech/Sci/R&D Officer | 44 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 30/11/21 | |
Timothy A. Wicks
BRD | Director/Board Member | 58 | 13/06/22 |
Corey McCann
BRD | Director/Board Member | 45 | 30/11/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 18 M€ | +2.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/04/24 | - | +-NaN% | 1 |
Delayed Quote OTC Markets, March 22, 2024 at 02:03 pm
More quotes
Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâs pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 142 | |
| +2.16% | 42.75B | |
| +47.58% | 41.61B | |
| +12.37% | 41.34B | |
| -12.36% | 26.59B | |
| +8.68% | 25.49B | |
| -23.23% | 18.12B | |
| +30.25% | 12.24B | |
| -1.39% | 11.76B | |
| +8.61% | 11B |
- Stock Market
- Equities
- PEARQ Stock
